Introduction: Human tissues rely on complex cellular networks to function. Yet the biotechnology industry is focused on technologies at the cellular or even sub-cellular level. Intactis Bio is a C-corp founded in February 2024 that has developed and provisionally patented novel biomanufacturing methods, tissue culture equipment, and techniques to fabricate intact tissues. Intactis Bio’s first target is an engineered brain tissue for use in biocomputation and regenerative medicine.
Leadership Team:
Daniel Rodriguez-Granrose, PhD, PSM, (He/Any), Founder & CEO, has 14 years of industry experience including bioengineering leadership at every phase in development from pre-clinical through commercialization, successful GMP transfer of multiple drug products, a proven track record building and managing technical teams, publications in process development, tissue bioengineering, and artificial intelligence.
Additional leadership team contracts in negotiation.
We are currently seeking investment.
We are currently seeking electrophysiology, AI/ML, and tissue engineers.
For inquiries please fill out our contact form.